Home> News> HARMONY Alliance results and presentations at ASH2021, the 63nd Annual Meeting of the American Society of Hematology
December 06, 2021 09:31 - x 00, 0 - 00:00
HARMONY researchers will present new results that may improve the prognostication of patients with Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL). This knowledge may be used to identify high-risk patients and to make better-informed treatment choices in the future.
Representatives of ASH, FDA, ASH Research Collaborative and HARMONY will participate in an inspiring session about the role of Real-World Data collection in Hematologic Malignancies. This Special-Interest session will take place on December 12, 2021 at 04:30-06:00 pm EST (Registered ASH2021 participants can participate either virtual or in person at the meeting venue: Georgia World Congress Center, B312-B314). Topics that will be addressed:
ASH 2021 will feature three HARMONY contributions related to acute myeloid leukemia (AML). Using data from thousands of patients with AML, HARMONY researchers have produced new insights that may be used to identify high-risk patients and to make better-informed treatment choices in the future.
ASH2021 | 608 | Azibeiro Melchor et al. studied gene-gene interactions in thousands of patients with AML. The HARMONY research team discovered that a mutation in the RAD21 gene has a positive effect on outcome in a particular group of patients. Link to abstract >
ASH2021 | 4041 | Sobas et al. developed a machine learning tool that can be used to assess the risk of relapse in certain patients with AML. Based on patient characteristics such as age, gender, molecular genetic mutations, and cytogenetic abnormalities, the tool graphically provides the probability of Relapse-Free Survival over time. Link to abstract >
AHS2021 | 3438 | Matteuzzi et al Studied AML molecular subclasses with advanced clustering methods observing differences in mutational patterns between males and females. At ASH2021 will be discussed if and how this affects patient outcomes. Link to abstract >
At ASH 2021, HARMONY researchers will present new results related to Chronic Lymphocytic Leukemia (CLL). Using data from thousands of patients with CLL, they have produced new insights that may be used to identify patients with an unfavorable prognosis. This may result in better-informed treatment choices in the future.
ASH2021 | 2617 | In a study of the European Research Initiative on CLL (ERIC) within HARMONY, Mansouri et al. investigated the prognostic impact of genomic aberrations in patients with Chronic Lymphocytic Leukemia. The results may help to identify patients with an unfavorable prognosis, with obvious implications for therapy choice. Link to abstract >
12 December 2021; 4:30-6:00PM EST - Georgia World Congress Center, B312-B314
There is an increasing interest in the role of Real World Data (RWD) to accelerate research and speed-up drug development for more effective treatments of blood cancer patients. The HARMONY Alliance, a European Public-Private Partnership for Big Data in Hematology, is collecting RWD from multiple sources and has built a secure Big Data platform, with >90,000 anonymized patient records identified. HARMONY Research teams are using innovative HARMONY Big Data analytic tools to answer critical research questions that cannot be addressed with other methods. The HARMONY Alliance unites over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. The ASH Research Collaborative is a non-profit organization established by the American Society of Hematology. The ASH Research Collaborative Data Hub aims to create the largest shared information resource within the global hematology community.
The inspiring Special-Interest Session will address Challenges and Potential Solutions to Accelerate Research, Regulatory Perspective on Data sharing and RWD to generate RWE, Patients Viewpoint on Real World Data Sharing and Clinical Viewpoints on Real World Data for Research. Expert views are shared by the American Society for Hematology, by the U.S. Food and Drug Administration, by the ASH Research Collaborative and by the HARMONY Alliance. As a starting point for a meaningful cross-Atlantic collaboration between ASH Research Collaborative Data Hub and the HARMONY Alliance, clinical viewpoints on RWD are offered in Multiple Myeloma and Acute Myeloid Leukemia.
Digital flyer: click here to view speakers and program >
As part of their ASH2021 content, the Video Journal of Hematological Oncology interviewed the HARMONY Co-Chair, Guillermo Sanz, click here to watch the video >
Relevant links
#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.
The HARMONY Alliance is a European public-private partnership of more than 100 hospitals, research institutes, medical associations, patient organizations, pharmaceutical companies, regulatory agencies, and IT companies. They jointly aim to accelerate the development of more effective treatments for blood cancer patients.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
